It’s a watershed moment when a technology that’s previously only been successful in academic settings becomes a real, scalable product.
San Diego, CA (PRWEB) December 10, 2015
Nanomedical Diagnostics, a biotech company developing and commercializing cutting-edge graphene biosensor technology for use in research and diagnostics, announces its scientific advisory board of leading scientists and medical researchers. The board will serve as a key resource to the company as it completes beta tests of its new sensitive life science research tool, AGILE Research.
“We are honored and thrilled to work with our esteemed scientific board of advisors,” says Nanomed CEO, Ross Bundy. “The knowledge and experience the members bring to the company is invaluable as we prepare to launch AGILE Research and begin laying the foundation for investigational product evaluation and market clearance of AGILE Dx for Lyme Disease.”
Timothy J. Broderick is the Chief Science Officer of Wright State Research Institute and Associate Dean for Research Affairs for the Wright State University Boonshoft School of Medicine. He is a surgeon and biomedical engineer who brings a wealth of experience in nanoscale medical development to the company. “In my prior service as a DARPA Program Manager, I had the opportunity to evaluate many nanomedical technologies,” says Dr. Broderick. “I’m excited to partner with a company that has a viable graphene BioFET sensor technology and a great potential to improve medical diagnostics.”
Robert C. Dynes is a University of California President Emeritus, UCSD Chancellor Emeritus, and top industrial scientist. With his career spanning 22 years at AT&T Bell Laboratories where he served as department head of semiconductor and material physics research and director of chemical physics research, Dr. Dynes brings his broad experience translating laboratory research into commercial products to Nanomed. “It’s a watershed moment when a technology that’s previously only been successful in academic settings becomes a real, scalable product,” says Dr. Dynes. “I believe Nanomed’s novel graphene biosensors have powerful, far-reaching potential.”
Jayakumar Rajadas is the Founding Director of the Biomaterials and Advanced Drug Delivery Lab and Assistant Director of Cardiovascular Pharmacology at the Stanford School of Medicine. He is an active medical researcher with extensive experience in emerging technologies. “I’m excited to be part of the launch of AGILE Research,” says Dr. Rajadas. “Nanomed’s biosensors have the potential to make a significant contribution to disease research and clinical diagnostics.”
AGILE Research is a label-free, sensitive, quantitative biosensor for biomolecular analysis and small molecule drug discovery that uses small sample volumes and can sense in complex solutions. Nanomed will hold daily demonstrations of the novel research tool at the American Society for Cell Biology Conference in San Diego from December 13 through 15.
For more information about Nanomed or AGILE Research, including pre-sale opportunities, visit http://www.nanomedicaldiagnostics.com. AGILE Research is slated to launch early 2016 for research use only.
Nanomedical Diagnostics (“Nanomed”) is the first biotech company to combine expertise in biology, nanotechnology, surface chemistry, engineering, and manufacturing to create practical and scaleable graphene biological field effect transistor (BioFET) products. Our ongoing mission is applying our cutting-edge capabilities to produce affordable diagnostic and monitoring platforms that deliver accurate, timely health information and improve patient outcomes and lives.